Arbutus Biopharma stock has delivered a strong 126.4% return over the past three years, yet its current valuation checks and market multiples suggest the shares are not a clear bargain at recent levels.

• Over the last three years, Arbutus Biopharma has returned 126.4%, which puts extra focus on whether the current share price already reflects much of the good news investors are hoping for.
• Expectations around the company’s ability to turn its pipeline and research into durable cash flows can support the current valuation, while execution risks and the need to fund ongoing development may weigh on what investors are willing to pay.
• Arbutus Biopharma scores 2 out of 6 on Simply Wall St’s broader valuation checks, which leans expensive rather than a clear bargain on that framework, as shown in this valuation summary.

The key question now is whether Arbutus Biopharma’s current price offers enough margin of safety after this multi year run, or if the recent gains already reflect most of the upside that investors might reasonably expect.

Has Arbutus Biopharma Run Too Far on Earnings?

The P/E ratio is a useful check on Arbutus Biopharma because it links today’s share price directly to the earnings that support it. Right now the stock trades on a P/E of about 6.3x, which is roughly half the Biotechs industry average of 17.5x and also below the peer group average of 12.4x.

However, Simply Wall St’s fair P/E ratio for Arbutus Biopharma is 1.5x, based on a model that weighs the company’s growth profile, margins, size and risk. The current 6.3x is therefore much higher than this tailored benchmark, and the gap is described as extreme because the model is heavily penalising the company’s current losses and forecast free cash flows. Rather than treating 1.5x as a precise target, it is better read as a signal that, on this framework, Arbutus Biopharma stock screens as expensive relative to what the underlying earnings and risk profile might justify.

On the P/E multiple, Arbutus Biopharma stock looks overvalued compared with what this earnings based model suggests would be a more reasonable level.

The Arbutus Biopharma Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Arbutus Biopharma pick up where the P/E discussion leaves off. They spell out which combinations of future growth, margins and earnings would need to play out for the stock to be worth materially more or less than today’s price. Each narrative ties its number to a clear view on how Arbutus Biopharma's growth, profitability and risks might evolve, giving you something specific to compare against as new information comes through.

If you have a number driven view on where Arbutus Biopharma's growth, margins and execution go from here, this is a chance to be one of the first voices in the Simply Wall St community to set it out as a clear narrative.

Present your case, choose the assumptions you think matter most, and observe how your thesis holds up as fresh results and updates are released.

Do you think there's more to the story for Arbutus Biopharma? Head over to our Community to see what others are saying!

The Bottom Line

For Arbutus Biopharma, the current P/E based checks point to an overvalued stock on the Simply Wall St framework, with a wide gap between today’s multiple and the fair ratio estimate. That gap exists because the tailored model heavily penalises current losses and the profile of expected cash flows, so the market is already pricing in a fair amount of execution success. From here, the key question is whether Arbutus Biopharma can convert its pipeline into sustainable earnings quickly enough to justify that richer multiple rather than leaving investors paying up for results that take longer to arrive.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.